Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 2
2006 2
2007 1
2008 5
2009 4
2010 4
2011 2
2012 2
2013 3
2014 2
2015 1
2016 2
2018 4
2019 9
2020 4
2021 2
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. Cappellini MD, et al. Among authors: voskaridou e. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. N Engl J Med. 2020. PMID: 32212518 Clinical Trial.
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators. Taher AT, et al. Among authors: voskaridou e. Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22. Lancet Haematol. 2022. PMID: 36007538 Clinical Trial.
Novel Therapeutic Advances in β-Thalassemia.
Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E. Makis A, et al. Among authors: voskaridou e. Biology (Basel). 2021 Jun 18;10(6):546. doi: 10.3390/biology10060546. Biology (Basel). 2021. PMID: 34207028 Free PMC article. Review.
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD, Taher AT, Piga A, Shah F, Voskaridou E, Viprakasit V, Porter JB, Hermine O, Neufeld EJ, Thompson AA, Tang D, Yucel A, Lord-Bessen J, Yu P, Guo S, Shetty JK, Miteva D, Zinger T, Backstrom JT, Oliva EN. Cappellini MD, et al. Among authors: voskaridou e. Eur J Haematol. 2023 Jul;111(1):113-124. doi: 10.1111/ejh.13975. Epub 2023 Apr 24. Eur J Haematol. 2023. PMID: 37095595 Clinical Trial.
2017 Clinical trials update in new treatments of β-thalassemia.
Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E. Makis A, et al. Among authors: voskaridou e. Am J Hematol. 2016 Nov;91(11):1135-1145. doi: 10.1002/ajh.24530. Am J Hematol. 2016. PMID: 27502996 Free article. Review.
The effect of transfusion on immune responses in thalassemia.
Politou M, Komninaka V, Valsami S, Kapsimali V, Pouliakis A, Koutsouri T, Panayiotakopoulos G, Kotsianidis I, Voskaridou E. Politou M, et al. Among authors: voskaridou e. Blood Cells Mol Dis. 2020 Jul;83:102425. doi: 10.1016/j.bcmd.2020.102425. Epub 2020 Mar 31. Blood Cells Mol Dis. 2020. PMID: 32244102
57 results